SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of competing RRP treatment Voceryq has put Precigens PAPZIMEOS in focus, with traders debating whether the new entrant will erode its sales. Bears see a direct competitive threat, while bulls point to PAPZIMEOS full approval and commercial head start and question Inovios ability to commercialize an accelerated-approval drug.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional-market launch and treasury-backed institutional finance push, which traders view as a potential catalyst alongside the protocols planned upgrades. Optimism about COMPs limited supply and a possible breakout is tempered by complaints that it continues to lag other crypto assets.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 report and stronger-than-expected Q4 profit outlook are driving attention, with shares rising despite revenue and EPS misses. Traders are focused on subscriber growth and improved margins, while some question the rally given the earnings shortfall and higher expenses.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios shares sold off despite a quarterly earnings beat as its outlook signaled slower organic growth, prompting concerns about deceleration and softer guidance. Traders are split between viewing the drop as an overreaction and buy-the-dip opportunity, and seeing the slower outlook as outweighing the results; some remain positive on Twilios longer-term AI communications potential.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is drawing attention amid a broad selloff in Chinese equities, with traders citing the CSI 300s bear-market decline, weak domestic demand and added uncertainty around AI export restrictions. The community is divided between warnings of a prolonged downturn and views that beaten-down China shares may be nearing a base.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Attention is centered on Zebecs payroll and payments integrations, particularly the MoneyGram/Stellar connection and a reported Germany/AllUnity deployment, which bullish traders view as adoption catalysts. Skeptics counter that partnership news has yet to translate into sustained token demand or price strength, while speculation about additional Robinhood or Ripple links remains unconfirmed.

OpenAI

OpenAIs potential IPO is driving attention, with traders debating reports that the listing could slip to 2027 amid market volatility and heightened safety and legal scrutiny. The discussion is split between enthusiasm for a major AI listing and skepticism about OpenAIs valuation, cash burn, and ability to sustain growth against competitors.

Artificial Superintelligence Alliance (FET) is a cryptocurrency launched in 2018. Artificial Superintelligence Alliance has a current supply of 2,714,384,546.672 with 2,419,135,848.3909366 in circulation. The last known price of Artificial Superintelligence Alliance is 0.16707757 USD and is up 1.84 over the last 24 hours. It is currently trading on 592 active market(s) with $193,186,396.23 traded over the last 24 hours. More information can be found at https://superintelligence.io/.

Fetch.ai

FETs price action and its place in the AI-crypto trade dominate the discussion, with traders watching for a breakout and describing relative strength during broader market weakness. Bullish dip-buying and accumulation hopes coexist with frustration over lagging performance and concern that Bitcoin weakness could weigh on the token.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of whether the S&P 500 rally is broadening beyond mega-cap tech, with traders highlighting its relative strength and recent highs as evidence of rotation into the average stock. Others warn that participation remains uneven and question whether the rotation can persist, especially as technology leadership shifts.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The Crocs Brand segment refers to the United States, South Korea, China, Japan, Singapore, Canada, Germany, Great Britain, France, Malaysia, Australia, Puerto Rico, the Netherlands, Australia, India, and Ireland. The HEYDUDE Brand segment focuses on the United States. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is drawing attention after quarterly results topped expectations and management raised its outlook, citing a continuing HEYDUDE recovery and steady demand for its core brand; the news fueled a sharp rally. Traders are cheering the breakout, while others warn of profit-taking and point to continued weakness in North American sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug

Equity

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 


Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.


uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.


Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.


Invesco Exchange-Traded Fund Trust II - Invesco Nasdaq Biotechnology ETF

Bearish Sentiment

<ul class="summary-bullets"><li>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe and as a biosimilar to Xgeva 70 mg/mL single-use vial.</li><li>STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.&nbsp;</li><li>The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.</li></ul>Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and Xgeva, containing the active ingredient denosumab, and used widely to manage osteoporosis.According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193283/0/en/Alvotech-Announces-Approval-of-AVT03-a-Biosimilar-to-Prolia-and-Xgeva-denosumab-in-the-European-Economic-Area.html">to</a> Alvotech, the European denosumab market is currently valued at approximately $1.2 billion across all indications. While widely used to manage osteoporosis, it is also used to prevent skeletal-related events in patients with certain cancers. Osteoporosis is a disease in which your bones become weak and are more prone to fracture due to a decrease in bone mineral density and bone mass.<h2 class="st-heading-2">EC Approval</h2>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe for the treatment of osteoporosis and bone loss, and as a biosimilar to Xgeva 70 mg/mL single-use vial for the prevention of skeletal-related events in adults with advanced malignancies involving bone.AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. &nbsp;STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded flat in the pre-market session at the time of writing. On Stocktwits, retail sentiment around ALVO jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 61% this year and by 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT">Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Alvotech company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 

Alvotech

Invesco Nasdaq Biotechnology ETF

Invesco FTSE RAFI US 1500 Small-Mid ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$36.17
Prev Close	$36.17
Open	$36.33
Dividend Yield	N/A
50-Day Moving Average	$35.04
Beta	N/A
Avg. Volume	32,747.73
PE Ratio	N/A

52-Week High	$36.95
52-Week Low	$26.00
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

IBBQ Fundamentals